文献速递特殊人群用药治疗药物监测与药物基因组学

囊性纤维化患儿中Lumacaftor/Ivacaftor群体药代动力学:迈向个体化治疗的第一步

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.
PubMed 文献 · Clin Pharmacokinet · 2024-02-04

本研究在75例囊性纤维化患儿中建立lumacaftor和ivacaftor的群体药代动力学模型,每个化合物及已知代谢物各191个浓度数据。分析发现体重和肝功能(AST)是患者间变异的主要来源,治疗48周后ivacaftor暴露水平与FEV1统计学相关。提示识别变异因素后需调整剂量,治疗药物监测可能有助于优化儿童给药。

要点

  • 体重和肝功能(AST)是lumacaftor/ivacaftor在患儿中暴露变异的主要来源
  • 治疗48周后ivacaftor暴露水平与FEV1统计学相关
  • 建议识别变异因素后调整剂量,治疗药物监测可能有助于个体化给药

核心结论

  • 这是首个在囊性纤维化患儿中开展的lumacaftor/ivacaftor群体药代动力学分析。
  • 数据提示识别变异因素后需调整剂量以优化疗效,治疗药物监测作为儿童剂量调整依据可能有用。

研究设计与样本

  • 群体药代动力学研究,纳入75例囊性纤维化患儿。
  • 每种化合物及已知代谢物(lumacaftor、ivacaftor、ivacaftor-M1、ivacaftor-M6)各有191个浓度数据。
  • 使用Monolix软件进行群体药代动力学分析。

主要发现

  • 观察到较大的个体间变异。
  • 患者间变异的主要来源为体重和肝功能(以天冬氨酸氨基转移酶评估)。
  • 治疗48周后,FEV1与ivacaftor暴露水平统计学相关。

临床怎么用

  • 在囊性纤维化患儿中使用lumacaftor/ivacaftor时应关注体重和肝功能对暴露的影响。
  • 可考虑通过治疗药物监测指导剂量调整以优化疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A major breakthrough in cystic fibrosis (CF) therapy was achievedAQ1 with CFTR modulators. The lumacaftor/ivacaftor combination is indicated for the treatment of CF in pediatric patients above 6 years old. Pharmacokinetic (PK) studies of lumacaftor/ivacaftor in these vulnerable pediatric populations are AQ2crucial to optimize treatment protocols. OBJECTIVES AND METHODS: The objectives of this study were to describe the population PK (PPK) of lumacaftor and ivacaftor in children with CF, and to identify factors associated with interindividual variability. The association between drug exposure and clinical response was also investigated. RESULTS: A total of 75 children were included in this PPK study, with 191 concentrations available for each compound and known metabolites (lumacaftor, ivacaftor, ivacaftor-M1, and ivacaftor-M6). PPK analysis was performed using Monolix software. A large interindividual variability was observed. The main sources of interpatient variability identified were patient bodyweight and hepatic function (aspartate aminotransferase). Forced expiratory volume in the first second (FEV1) was statistically associated with the level of exposure to ivacaftor after 48 weeks of treatment. CONCLUSIONS: This study is the first analysis of lumacaftor/ivacaftor PPK in children with CF. These data suggest that dose adjustment is required after identifying variability factors to optimize efficacy. The use of therapeutic drug monitoring as a basis for dose adjustment in children with CF may be useful.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Bouazza N, Urien S, Foissac F, et al. Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy. Clin Pharmacokinet. 2024. PMID: 38310629. doi:10.1007/s40262-023-01342-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。